肝内胆管癌转化治疗

肝内胆管癌（ICC）可切除率低，进展期ICC的治疗有效率不高，预后很差。转化治疗在多种晚期肿瘤中有一定的疗效，是目前晚期肿瘤治疗的研究热点。随着对ICC基因组的深入了解和新的治疗药物的开发及组合，基于系统化疗的联合治疗策略，精准靶向治疗，免疫检查点抑制剂等显示出较好的疗效，使得部分进展期ICC病人能降期转化手术，获得长期生存。     

SALVAGE THERAPY IN PATIENTS WITH UNRESECTABLE HILAR CHOLANGIOCARCINOMA

We describe our methods and outcomes of multidisciplinary treatments in patients with unresectable hilar cholangiocarcinoma. Fifty‐seven patients with a known outcome were enrolled. Thirty‐four of 57 patients were treated and evaluated by salvage therapy. For salvage therapy, we used internal and external radiotherapy, photodynamic therapy, YAG laser therapy and microwave coagulation therapy. The median survival time was 548 days for the group receiving salvage therapy and 198 days for the group not receiving this treatment. In conclusion, although no randomization of the patients was performed in this retrospective study, our present data provide convincing evidence that salvage therapy is a useful therapeutic approach for unresectable hilar cholangiocarcinomas.     

肝门胆管癌的动态增强CT诊断

目的评价螺旋CT对肝门胆管癌的诊断价值。方法13例肝门胆管癌行螺旋CT平扫及动态增强扫描,并与手术及病理对照分析。结果11例平扫表现为肝门区低密度软组织肿块;2例表现为肝门区胆管不规则增厚,管腔狭窄。增强扫描13例有延迟强化。结论螺旋CT扫描对肝门胆管癌的诊断具有重要意义。     

nm23-H1基因转染对人胆管癌细胞系QBC939体外浸润能力的影响

目的：探讨nm23-H1基因转染对人胆管癌细胞系QBC939体外浸润能力的影响。方法：将含有全长nm23-H1 cDNA的真核表达载体通过脂腩体法转染人胆管癌细胞系。结果：转染成功的QBC939细胞，其nm23-Hl基因的mRNA、蛋白表达明显增加，转染nm23-H1基因的胆管癌细胞体外浸润能力下降，穿越matrigel的细胞数明显低于亲本QBC939细胞，代表浸润能力的IV型胶原酶（MMP-9）分泌量下降。结论：nm23-Hl基因可以抑制胆管癌细胞的体外浸润能力。     

肝胆管结石合并胆管癌的诊治

目的 :讨论肝胆管结石合并胆管癌的临床特点和诊治方法。方法 :对 11例肝胆管结石合并胆管癌的临床资料进行回顾性研究。结果 :本组肝胆管结石合并胆管癌的术前确诊率为 18.2 % (2 /11) ;术中冰冻病理检查确诊 2例 ;术后病理证实 7例。肝门胆管癌 72 .7% (8/11) ,中段胆管癌 9.1% (1/11) ,下段胆管癌 18.2 % (2 /11)。肿瘤根治切除率 36 .4 % (4/11) ,姑息性手术 6 3.6 % (7/11)。结论 :提高对本病的认识及详细的术中探查是及早发现胆管癌的重要途径。胆管癌根治性切除明显优于姑息性手术。     

不同临床和病理分型对肝门部胆管癌切除术预后的影响

目的 研究临床和病理分型与肝门部胆管癌切除术疗效的关系。方法总结1993年至2004年在解放军总医院肝胆外科手术切除的肝门部胆管癌198例病例资料。结果临床分型Ⅰ型34例，Ⅱ型60例，Ⅲa型27例，Ⅲb型33例，Ⅳ型19例，Ⅴa型6例。Ⅴb型19例。病理高分化腺癌35例，中分化腺癌52例，低分化腺癌54例，三者的中位生存期分别为29．5、11、5．5个月；病理切缘阴性者与切缘阳性者生存率有显著性差异（P 〈0．05）。手术并发症出现率41．4％，围手术期死亡1例。结论肝门部胆管癌根据临床分型进行相应的手术治疗；病理切缘阴性是影响预后的主要因素之一；围手术期正确处理，是减少手术并发症，提高患者生活质量和延长生存期的关键。     

肝内胆管细胞癌的CT表现

目的分析胆管细胞癌的CT表现,提高对胆管细胞癌的认识。方法回顾性分析经病理证实的21例胆管细胞癌的CT表现。结果CT平扫所有病例均为单发低密度灶。CT增强扫描21例不均匀轻度强化,其中4例出现大片无强化低密度区,部分边缘强化,2例病灶延迟强化,17例肝内胆管扩张。结论CT是胆管细胞癌的重要影像检查方法,不均匀强化病灶内可见胆管扩张是胆管细胞癌的重要征象。     

双抗体夹心法检测胆管癌患者血清中胆管癌相关抗原的临床意义

胆管癌相关抗原（ＣＣＲＡ）是我们从人胆管癌组织中提取的一种新的肿瘤标志物。建立了检测ＣＣＲＡ的ＥＬＩＳＡ方法，检测了４０例正常人及２６８例良恶性疾病病人血清的ＣＣＲＡ浓度，后者包括胆管癌３６例、原发性肝癌４０例、胰腺癌２６例、胃癌３１例、结直肠癌３４例、肺癌１７例、肝硬变２０例、胆石症４０例及胃溃疡２４例。结果显示：４０例正常对照组的血清ＣＣＲＡ浓度为（１４．３８±７．３４）μｇ／ｍｌ（ｘ±ｓ），正常上限为２８．９５μｇ／ｍｌ（ｘ＋２ｓ）；血清ＣＣＲＡ诊断胆管癌的敏感性是７７．７８％，明显高于其它肿瘤组（０～２５）％（Ｐ＜０．００１），特异性是（７５～１００）％。认为对于胆管癌的诊断，ＣＣＲＡ可能是一种较特异的肿瘤相关抗原。     

Absence of Epstein-Barr virus (EBV) in intrahepatic cholangiocarcinoma confirmed by lack of EBV-coded nuclear RNA and latent membrane protein-1

AIMS: Studies are disclosing that Epstein-Barr virus (EBV) is involved in the aetiology of various neoplasms including undifferentiated carcinomas of the aerodigestive tract. The aetiology of intrahepatic cholangiocarcinoma (ICC), a malignant neoplasm arising from intrahepatic biliary epithelia, has yet to be fully evaluated. To date, two cases of EBV-related ICC have been reported, and they presented foci of lymphoepitheliomatous undifferentiated carcinoma components. METHODS AND RESULTS: To determine whether EBV is commonly involved in the developments of ICC, we performed in-situ hybridization and immunohistochemistry for EBV in 215 cases of ICC in Japan, using a probe against EBV-coded nuclear RNA (EBER) and a specific antibody against latent membrane protein-1 (LMP-1), respectively. We did not detect EBV-infected carcinoma cells in any of the ICC cases examined. No lymphoepitheliomatous undifferentiated carcinoma components were found either. CONCLUSION: The results suggest that EBV infection is unlikely to be involved in the pathogenesis of ICC.